155 related articles for article (PubMed ID: 32677746)
1. Apolipoprotein C-III O-glycoform profiling of 500 serum samples by matrix-assisted laser desorption/ionization mass spectrometry for diagnosis of congenital disorders of glycosylation.
Wada Y; Okamoto N
J Mass Spectrom; 2021 Apr; 56(4):e4597. PubMed ID: 32677746
[TBL] [Abstract][Full Text] [Related]
2. MALDI-MS profiling of serum O-glycosylation and N-glycosylation in COG5-CDG.
Palmigiano A; Bua RO; Barone R; Rymen D; Régal L; Deconinck N; Dionisi-Vici C; Fung CW; Garozzo D; Jaeken J; Sturiale L
J Mass Spectrom; 2017 Jun; 52(6):372-377. PubMed ID: 28444691
[TBL] [Abstract][Full Text] [Related]
3. MALDI-TOF MS applied to apoC-III glycoforms of patients with congenital disorders affecting O-glycosylation. Comparison with two-dimensional electrophoresis.
Yen-Nicolaÿ S; Boursier C; Rio M; Lefeber DJ; Pilon A; Seta N; Bruneel A
Proteomics Clin Appl; 2015 Aug; 9(7-8):787-93. PubMed ID: 25641685
[TBL] [Abstract][Full Text] [Related]
4. Plasma N-glycan profiling by mass spectrometry for congenital disorders of glycosylation type II.
Guillard M; Morava E; van Delft FL; Hague R; Körner C; Adamowicz M; Wevers RA; Lefeber DJ
Clin Chem; 2011 Apr; 57(4):593-602. PubMed ID: 21273509
[TBL] [Abstract][Full Text] [Related]
5. Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry to Detect Diagnostic Glycopeptide Markers of Congenital Disorders of Glycosylation.
Wada Y
Mass Spectrom (Tokyo); 2020; 9(1):A0084. PubMed ID: 32547898
[TBL] [Abstract][Full Text] [Related]
6. Mass spectrometry of transferrin and apolipoprotein C-III for diagnosis and screening of congenital disorder of glycosylation.
Wada Y
Glycoconj J; 2016 Jun; 33(3):297-307. PubMed ID: 26873821
[TBL] [Abstract][Full Text] [Related]
7. Electrospray Ionization Mass Spectrometry of Apolipoprotein CIII to Evaluate
Wada Y; Okamoto N
Mass Spectrom (Tokyo); 2022; 11(1):A0104. PubMed ID: 36060528
[TBL] [Abstract][Full Text] [Related]
8. Relative quantification of plasma N-glycans in type II congenital disorder of glycosylation patients by mass spectrometry.
Barbosa EA; Fontes NDC; Santos SCL; Lefeber DJ; Bloch C; Brum JM; Brand GD
Clin Chim Acta; 2019 May; 492():102-113. PubMed ID: 30776362
[TBL] [Abstract][Full Text] [Related]
9. Mass spectrometry of apolipoprotein C-III, a simple analytical method for mucin-type O-glycosylation and its application to an autosomal recessive cutis laxa type-2 (ARCL2) patient.
Wada Y; Kadoya M; Okamoto N
Glycobiology; 2012 Aug; 22(8):1140-4. PubMed ID: 22611120
[TBL] [Abstract][Full Text] [Related]
10. Glycosylation Analysis for Congenital Disorders of Glycosylation.
Li X; Raihan MA; Reynoso FJ; He M
Curr Protoc Hum Genet; 2015 Jul; 86():17.18.1-17.18.22. PubMed ID: 26132001
[TBL] [Abstract][Full Text] [Related]
11. Mass spectrometry glycophenotype characterization of ALG2-CDG in Argentinean patients with a new genetic variant in homozygosis.
Papazoglu GM; Cubilla M; Pereyra M; de Kremer RD; Pérez B; Sturiale L; Asteggiano CG
Glycoconj J; 2021 Apr; 38(2):191-200. PubMed ID: 33644825
[TBL] [Abstract][Full Text] [Related]
12. Serum N-glycan and O-glycan analysis by mass spectrometry for diagnosis of congenital disorders of glycosylation.
Xia B; Zhang W; Li X; Jiang R; Harper T; Liu R; Cummings RD; He M
Anal Biochem; 2013 Nov; 442(2):178-85. PubMed ID: 23928051
[TBL] [Abstract][Full Text] [Related]
13. The impact of mass spectrometry in the diagnosis of congenital disorders of glycosylation.
Sturiale L; Barone R; Garozzo D
J Inherit Metab Dis; 2011 Aug; 34(4):891-9. PubMed ID: 21384227
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein C-III isofocusing in the diagnosis of genetic defects in O-glycan biosynthesis.
Wopereis S; Grünewald S; Morava E; Penzien JM; Briones P; García-Silva MT; Demacker PN; Huijben KM; Wevers RA
Clin Chem; 2003 Nov; 49(11):1839-45. PubMed ID: 14578315
[TBL] [Abstract][Full Text] [Related]
15. Transferrin and apolipoprotein C-III isofocusing are complementary in the diagnosis of N- and O-glycan biosynthesis defects.
Wopereis S; Grünewald S; Huijben KM; Morava E; Mollicone R; van Engelen BG; Lefeber DJ; Wevers RA
Clin Chem; 2007 Feb; 53(2):180-7. PubMed ID: 17170056
[TBL] [Abstract][Full Text] [Related]
16. Complementarity of electrophoretic, mass spectrometric, and gene sequencing techniques for the diagnosis and characterization of congenital disorders of glycosylation.
Bruneel A; Cholet S; Drouin-Garraud V; Jacquemont ML; Cano A; Mégarbané A; Ruel C; Cheillan D; Dupré T; Vuillaumier-Barrot S; Seta N; Fenaille F
Electrophoresis; 2018 Dec; 39(24):3123-3132. PubMed ID: 29869806
[TBL] [Abstract][Full Text] [Related]
17. Insights into complexity of congenital disorders of glycosylation.
Goreta SS; Dabelic S; Dumic J
Biochem Med (Zagreb); 2012; 22(2):156-70. PubMed ID: 22838182
[TBL] [Abstract][Full Text] [Related]
18. Identification of new apolipoprotein-CIII glycoforms with ultrahigh resolution MALDI-FTICR mass spectrometry of human sera.
Nicolardi S; van der Burgt YE; Dragan I; Hensbergen PJ; Deelder AM
J Proteome Res; 2013 May; 12(5):2260-8. PubMed ID: 23527852
[TBL] [Abstract][Full Text] [Related]
19. Increased Clinical Sensitivity and Specificity of Plasma Protein
Chen J; Li X; Edmondson A; Meyers GD; Izumi K; Ackermann AM; Morava E; Ficicioglu C; Bennett MJ; He M
Clin Chem; 2019 May; 65(5):653-663. PubMed ID: 30770376
[TBL] [Abstract][Full Text] [Related]
20. Clinical and molecular diagnosis of non-phosphomannomutase 2 N-linked congenital disorders of glycosylation in Spain.
Medrano C; Vega A; Navarrete R; Ecay MJ; Calvo R; Pascual SI; Ruiz-Pons M; Toledo L; García-Jiménez I; Arroyo I; Campo A; Couce ML; Domingo-Jiménez MR; García-Silva MT; González-Gutiérrez-Solana L; Hierro L; Martín-Hernández E; Martínez-Pardo M; Roldán S; Tomás M; Cabrera JC; Mártinez-Bugallo F; Martín-Viota L; Vitoria-Miñana I; Lefeber DJ; Girós ML; Serrano Gimare M; Ugarte M; Pérez B; Pérez-Cerdá C
Clin Genet; 2019 May; 95(5):615-626. PubMed ID: 30653653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
